Enorama Pharma AB (ERMA) — Cash Flow-to-Debt Ratio
Enorama Pharma AB (ERMA) has a Cash Flow-to-Debt Ratio of -0.47x as of December 2025, meaning its operating cash flow of Skr-14.79 Million could theoretically repay 0% of its total liabilities (Skr31.71 Million) in one year. See Enorama Pharma AB free cash flow efficiency to measure how efficiently the company converts operating cash flow to free cash.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Enorama Pharma AB Cash Flow-to-Debt Ratio (2014–2025)
Historical debt coverage capacity for Enorama Pharma AB across 12 annual periods. Also explore Enorama Pharma AB (ERMA) equity growth momentum to track the company's year-over-year net asset growth rate.
Annual Cash Flow-to-Debt Ratio for Enorama Pharma AB (2014–2025)
Year-by-year debt coverage analysis for Enorama Pharma AB. For market capitalisation and broader financial context, see Enorama Pharma AB stock valuation.
| Year | CF-to-Debt Ratio | Operating CF (SEK) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -1.87x | Skr-59.26 Million | Skr31.71 Million | ▲ +57.7% |
| 2024 | -4.41x | Skr-35.70 Million | Skr8.09 Million | ▼ -58.4% |
| 2023 | -2.79x | Skr-41.35 Million | Skr14.85 Million | ▼ -45.3% |
| 2022 | -1.92x | Skr-32.96 Million | Skr17.20 Million | ▼ -87.9% |
| 2021 | -1.02x | Skr-30.16 Million | Skr29.58 Million | ▼ -73.5% |
| 2020 | -0.59x | Skr-23.00 Million | Skr39.13 Million | ▲ +21.7% |
| 2019 | -0.75x | Skr-26.56 Million | Skr35.40 Million | ▼ -22.5% |
| 2018 | -0.61x | Skr-13.36 Million | Skr21.81 Million | ▲ +25.3% |
| 2017 | -0.82x | Skr-6.67 Million | Skr8.13 Million | ▲ +39.0% |
| 2016 | -1.34x | Skr-6.11 Million | Skr4.55 Million | ▼ -840.8% |
| 2015 | 0.18x | Skr480.00K | Skr2.64 Million | ▼ -38.9% |
| 2014 | 0.30x | Skr307.00K | Skr1.03 Million | — |